Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection

NCT05196477 · clinicaltrials.gov ↗

COMPLETED

Status

3087

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: Olokizumab
DRUG: Standard therapy

Sponsor

R-Pharm

Collaborators

[object Object]
[object Object]
[object Object]